Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 115 clinical trials
Featured trial
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives

growth factor. The growth factor (granulocyte colony stimulating factor) is designed to increase the production of donor stem cells. In the second step white blood cell lymphocytes are removed from

  • 22 Dec, 2020
  • 1 location
Featured trial
Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease

Background: Peripheral blood stem cell transplantation procedures are used for people with sickle cell disease. Researchers want to improve the success and reduce the complications for these procedures. This might allow more people to have a transplant. Objective: To see if a new transplant regime is effective, safe and well …

cell transplantation
sickle cell disease
red blood cell disorder
  • 22 Dec, 2020
  • 1 location
Part II: Granulocyte-Colony Stimulating Factor Adjunct Therapy for Biliary Atresia (BA_GCSF2b)

The Investigators propose to test the hypothesis that GCSF enhances the clinical outcome of biliary atresia in a multi-institutional Phase 2 trial to prospectively evaluate the safety and efficacy of GCSF in each of the 2 groups of newly diagnosed BA patients: KBA (i.e., Kasai-operated) or NoK (i.e., patients who …

  • 04 Mar, 2022
  • 2 locations
Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer

The objective of this study is to determine the maximum safe dose of Ra-223 in combination with fractionated (split doses) docetaxel when given to subjects and to determine the best administering dose. The study will look at side effects that may happen while taking the combination treatment. A total of …

  • 10 Mar, 2022
  • 4 locations
LONsurf and G-CSF Use: Being On A Right Dose-intensity to Optimize Treatment Efficacy

Prospective cohort of patients treated with trifluridine/tipiracil, maximal sample size 250 patients. It is expected, that 89 patients will experience a grade 3-4 neutropenia and will be included in the phase II.

chemotherapy regimen
growth factor
  • 04 Feb, 2021
  • 19 locations
The Role of Allo-HSCT in MRD-negative Patients With AML Under the Age of 60 Years in the First Complete Remission

Depending on the variant of the disease, patients are divided into 3 groups: A, B and C. Group A include patients with acute myeloid leukemia (AML) inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11, group B - AML with t(8;21)(q22;q22.1); RUNX1-RUNX1T1, AML with normal karyotype with or without gene mutations (FLT3, NPM1, CEBPa) regardless …

  • 28 Apr, 2022
  • 1 location
GM-CSF Fosfomycin and Metronidazole for Pouchitis in Ulcerative Colitis Patients After Restorative IPAA Surgery

This study will examine whether the application of GM-CSF, fosfomycin and metronidazole locally in the pouch is safe and effective in the treatment of pouchitis for patients with ulcerative colitis, and whether treatment changes the microbiome of the pouch.

  • 20 Sep, 2021
  • 1 location
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow

to 101 weeks with naxitamab and granulocyte-macrophage colony stimulating factor (GM-CSF). Patients will be followed for up to five years after first dose. Naxitamab, also known as hu3F8 is a

monoclonal antibodies
colony stimulating factor
high-risk neuroblastoma
bone marrow procedure
  • 23 Mar, 2022
  • 23 locations
Long-acting G-CSF for Febrile Neutropenia

This study aims to analyze the effects of long-acting granulocyte colony stimulating factor (G-CSF) on the prevention febrile neutropenia (FN) in epithelial ovarian cancer. Patients are

epithelial ovarian cancer
colony stimulating factor
ovarian cancer
granulocyte colony stimulating factor
  • 22 Jan, 2021
Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma

stimulating factor (G-CSF) following every dose of A+AVD for 6 cycles of treatment (12 doses). Part A will look at whether the A+AVD drug combination reduces the number of participants who experience

measurable disease
chemotherapy regimen
colony stimulating factor
  • 16 May, 2022
  • 68 locations